This patent application concerns a process for the elimination of the use of chemicals in the pre-treatment of reverse osmosis seawater desalination plants. Therefore, the field of technology in which the invention is included is the water treatment industry, specifically the reverse osmosis desalination sector.
To date, reverse osmosis seawater desalination plants generally consist of the following stages: seawater collection, chemical pre-treatment (dosing of H2SO4, NaClO, FeCl3, MBS, and antifouling), physical pre-treatment by filtration in sand filters (20 micron porosity), spark plug filters (10 micron porosity) and spark plug filters (5 micron porosity or currently one micron porosity cartridge filters) and then on to the high pressure line, to the membrane racks where reverse osmosis takes place, with the brine flowing out of one side and into the sea, and the osmosed water that goes to the post-treatment system, and finally to distribution.
In desalination plants, it has been common practice to shock-dosage NaClO (50 ppm) into the seawater in the collection chamber for prior control of biological contamination, before it was pumped to the plant's pre-treatment line, where it received a second dosage of NaClO (50 ppm), as well as the other chemical dosages, carried out in excess, far from the optimal dosages.
Once the desalination plant has been built, the pre-treatment will have been sized for a nominal quality and flow of the water to be desalinated. Any increase in the feed flow would cause the physical and chemical pre-treatment processes not to function property, the membranes of the reverse osmosis unit would also not be affected, as the membranes would become fouled more quickly, requiring more frequent rinsing. The cost of washing includes a consumption of reagents, energy and previously produced desalinated water and a period of unproductivity. In addition, as the frequency of washes increases, the useful life of the membranes is shortened, forcing to replace them ahead of schedule. All this implies an increase in the cost of the water produced.
For reverse osmosis membranes to function properly, meeting the warranty requirements of the suppliers, require one or maximum two washes per year, which implies that the seawater that comes into contact with them must be of a specific quality, in particular with regard to their microbiological, particulate, dispersion and suspended particle content. The required quality of the seawater that is brought into contact with the reverse osmosis membranes can only be achieved with adequate pretreatment to adequately remove particulate matter and contaminating microbiology from the seawater.
A physical and chemical pre-treatment as used in today's conventional seawater desalination plants, do not guarantee the necessary quality of this water that is brought into contact with the reverse osmosis membranes, The problem of frequent membrane flushing, in addition to the problem of contamination of the marine aqueous environment, is therefore a problem, because of the discharge of the residual brine with a high content of the residual chemicals still contained in it.
For example, the dosing of NaClO, in order to eliminate microbiological contamination of seawater, is only effective in eliminating pathogenic micro-organisms, while other micro-organisms (viruses, bacteria, pyrogens, etc.), are only left in a state of dormancy (temporary inactivity, due to the presence of the biocide), which later when MBS (NaHSO3) is dosed to remove the residual NaClO, and thus prevent it from coming into contact with the active layer (usually polyamide) and damaging it by chemical oxidation, the dormant bacteria are reactivated and are also found with abundant food (microorganisms killed by NaClO), They reproduce extremely rapidly, causing very serious fouling problems through the formation of abundant biological mass (biofouling) on the active layer of the membranes.
Also, when it comes to removing the presence of dispersed and suspended particles (colloidal), by dosing FeCl3 (coagulant) and other coagulation aids (polyelectrolytes), in the different filtration units, the total removal of dispersed particles (of sizes >100 μm), in particular colloidal particles (of sizes between 1 and 100 μm), is not achieved, This also contributes to membrane fouling due to deposits of these particles on the active layer of the membrane (fouling).
Regarding the dosage of Hexa Meta Sodium Phosphate (HMFS), as an antifouling agent to control salt precipitation (scaling), due to the concentration polarisation process on the active layer of the membranes at the time when reverse osmosis is taking place, precipitation of a series of salts (CaCO3, CaSO4, BaSO4, SrSO4, CaF2, non-colloidal reactive SiO2), and to a lesser extent oxides or hydroxides of a microcrystalline nature (Fe, Mn, and Al), which are generally controlled in conventional reverse osmosis seawater desalination processes by dosing HMFS (Na6P6O18).
New in this application is a major modification to the pre-treatment section of existing conventional seawater desalination plants, and basically the different physical treatment units (sand filters with porosity of 20 μm, medium porosity filters of 10 μm, and small porosity filters or cartridge filters of 1 to 5 μm) are replaced, by Ultra Filtration membranes of the so-called MBR type. This innovative solution has been experimentally tested in a seawater desalination plant.
In order to achieve the above-mentioned design objectives, the invention consists of a new procedure for the pre-treatment of existing conventional seawater desalination plants.
In order to explain the differences and novelties of the invention, the basic stages of a conventional desalination plant are described first:
The present invention replaces the various physical treatment units (sand filters with a porosity of 20 μm, medium porosity filters with a porosity of 10 μm and fine porosity filters or cartridge filters with a porosity of 1 to 5 μm), by a single physical treatment unit using ultra-filtration membranes (MBR type) which eliminates the dosage of H2SO4, coagulants (FeCl3, Al2(SO4)3, AlCl3, etc.), NaClO or any other biocide to remove micro-organisms in seawater and MBS (NaHSO3) to remove residual NaClO. The dosing of HMFS as an antiscalant is replaced by the regulation of the pH (6-6.5) of the seawater, which will be fed to the reverse osmosis membrane rack.
To achieve the design objectives, the ultrafiltration membranes to be used are of the so-called MBR type and consist of hollow fiber membranes (with a porosity of 0.03 μm). The “outside-inside” operation, which operates by gentle suction of between 0.1 and 0.5 bar maximum, is structured in submersible cartridges, of the type generally used in domestic and industrial wastewater treatment, as opposed to UF membranes in “Spiral” configuration, that have been installed in the latest conventional desalination plants built in recent years.
These membranes in MBR configuration can retain dispersed particles (sizes >100 μm) as well as colloidal particles (sizes between 1 and 100 μm). This makes the dosing of coagulants (FeCl3, Al2(SO4)3, AlCl3, etc.) unnecessary. These ultrafiltration membranes are also capable of retaining micro-organisms present in seawater, such as bacteria (0.5 and 800 μm), viruses (0.01 and 0.1 μm) and even pyrogens (0.002 and 0.015 μm). Therefore, neither the dosing of NaClO, nor any other biocides to kill micro-organisms in seawater is unnecessary. Therefore, if the dosing of biocide is not necessary, the dosing of MBS (NaHSO3), which is intended to remove the residual NaClO, which, if it comes into contact with the reverse osmosis membranes, is not necessary either, with an active polyamide layer would damage it by chemical oxidation, nor is the dosing of H2SO4 necessary to enhance the action of the biocide and the coagulant, that both, in the novelty presented here, will not be dosed.
As for the control of membrane fouling because of concentration polarization, which causes the precipitation of different salts (CaCO3, CaSO4, BaSO4, SrSO4, CaF2). Silica (SiO2, reactive non-colloidal) from the different cations and anions present in seawater, which cause the so-called scaling fouling, the “autopsy” of membranes carried out in research work has been considered. These “autopsies” have shown that approximately 50% of the fouling materials are inorganic substances, The presence of silica, such as silica (SiO2), is of the order of 30%, the second largest being calcium carbonates, in the order of 6.4%, the rest of the salts are in negligible quantities. It is therefore possible to eliminate the dosing of antifouling agents such as sodium hexa meta phosphate (Na6P6O18), basically replacing it by a pH regulation of the seawater with H2SO4 in a pH range between 6 and 6.5, determined by the Langelier equation (1930), using the mathematical expression (pHs=log (Ks/K2)−log Ca++−log HCO3), where Ks and K2 are equilibrium constants that depend on the temperature and ionic strength of the water, and which allow the calculation of the saturation pH (pHs) of seawater, at which CaCO3 has no tendency to precipitate or dissolve; This pH value was experimentally determined and confirmed in a real process, the value of which is between 6 and 6.5, thus ensuring that no carbonate precipitation will occur during the reverse osmosis process in this pH range, or other salts, because the other salts have a higher saturation constant than carbonate, so that no chemical antifouling will be necessary.
This is the experimental justification, confirmed in a real seawater desalination plant, for the novelty presented in this patent application.
The advantages of this new pre-treatment are as follows:
To complement the description being made and to assist in a better understanding of the features of the invention, a set of drawings is attached hereto as an integral part of this description, in which the following is shown for illustrative and non-limiting purposes:
The following is a list of the different elements that make up a reverse osmosis seawater desalination plant, represented in the figures that make up the invention:
The invention consists of a new process for the pre-treatment of conventional reverse osmosis seawater desalination plants, characterized by replacing the different physical treatment units, such as the sand filters (6) and their washing system (7) with a porosity of 20 μm, plug filters (10) of medium porosity of 10 μm, and their backwashing system (11), and small porosity filters or cartridge filters (13) of 1 to 5 μm, and their backwashing system (14); by a single physical treatment unit using ultra-filtration membranes (23) of the MBR type. The H2SO4 dosing system (3), whose function was to enhance the action of both the biocide and the coagulant, was also eliminated, the NaClO or other biocide dosing system (4) designed to kill micro-organisms in seawater, the dosing system of any coagulants or flocculation aids (5) (FeCl3, Al2(SO4)3, AlCl3, etc.), the MBS dosing system (12) designed to remove residual chlorine from NaClO. As well as the dosage of any chemical antifouling (15), replaced by regulating the pH (25) between 6 and 6.5 of the seawater.
Specifically, the physical treatment units and dosages to be removed are as follows:
This patent application eliminates both physical and chemical pre-treatment, by incorporating an ultrafiltration system (23) consisting of submerged ultrafiltration membranes (MBR type), in hollow fiber configuration operating by suction from the outside to inside, operating at a vacuum pressure between 0.1 and 0.5 bar maximum.
These ultrafiltration membranes can retain the micro-organisms present in seawater, such as bacteria (0.5 and 800 μm), viruses (0.01 and 0.1 μm), including pyrogens (0.002 and 0.015 μm).
In this way, a seawater desalination plant, using “Reverse Osmosis” technology, structured with this innovation, is more compact and consists of the following stages:
This process also produces a chemically uncontaminated brine (20) for use in the simple production of table salt for human consumption and other industrial products (HCl, NaOH, etc.).
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/ES2020/070823 | 12/28/2020 | WO |